Company showcases pipeline developments and sub-studies from the revolutionary FLEX Registry with posters focused on patient-centric insights Two oral discussion sessions to focus on RUO ImPrint immune signature and BluePrint® whole transcriptomic analysis in Black Read More
Strategic hire underscores commitment to commercial growth across genomic assay portfolio IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – April 4 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used Read More
January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients Read More
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.